Drug intelligence / Profile preview

3rd generation GLP1 Analog

Development stage: Preclinical
Lead developer: Longevity Biotech
Modality: Peptides

Overview

3rd generation GLP1 Analog is a peptide-based glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Longevity Biotech for the treatment of obesity and weight loss. The candidate is engineered using the company's proprietary Hybridtide technology, which aims to create synthetic peptides with enhanced metabolic stability and resistance to protease degradation compared to natural peptides. By activating the GLP-1 receptor, the analog is intended to regulate appetite and glucose homeostasis. As of the latest reports, the program is in the discovery stage of development.

Other names: GLP-1 receptor-peptideGLP1 receptor-peptideGLP 1 receptor-peptideGLP-1 analogGLP1 analogGLP 1 analog

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on 3rd generation GLP1 Analog.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3rd generation GLP1 Analog.

Explore the full profile